HomeNewsIndiaCOVID-19 pandemic | Amit Shah says RTPCR capacity to be doubled in Delhi, along with an additional 300 ICU beds

COVID-19 pandemic | Amit Shah says RTPCR capacity to be doubled in Delhi, along with an additional 300 ICU beds

Delhi recorded 3,235 fresh COVID-19 cases, taking the infection tally to over 4.85 lakh on Sunday, while ninety-five more fatalities pushed the death toll to 7,614.

November 15, 2020 / 20:29 IST
Story continues below Advertisement

Union Home Minister Amit Shah on November 15 took stock of Delhi’s COVID-19 situation in the wake of a recent spike in cases in the national capital, officials said.

To deal with the recent spike in coronavirus cases in Delhi, the Centre on Sunday said it will soon make available 300 additional ICU beds and double the number of daily RTPCR tests in the national capital.

Story continues below Advertisement

Delhi Lieutenant Governor Anil Baijal, Chief Minister Arvind Kejriwal, Union Health Minister Harsh Vardhan, Delhi Health Minister Satyendar Jain and senior officers of the central government attended the meeting chaired by Shah.

The home minister reviewed the situation arising due to the spike in COVID-19 cases in Delhi and discussed ways to deal with it.  He said in the meeting that 300 ICU beds will be made available at the DRDO COVID hospital (Dhaula Kuan) in addition to the existing 250 ICU beds

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show